Cystic fibrosis and Trikafta in Canada
November 21, 2024 — Cystic fibrosis (CF) is a rare genetic disease affecting the lungs and other internal organs. In 2022, approximately 4,445 CanadiansReference1 were living with the disease. There is no cure for CF; however, in June 2021, a new drug treatment option — Trikafta — was approved. This analysis looks at how patients’ health system use changes when they are started on this new drug treatment.
Key findings
- The biggest impact of Trikafta for people with CF was a decrease in need for acute care
- Routine care saw less immediate change with Trikafta use
- There is inequity in access to Trikafta across Canada
Featured material
Impact of Trikafta on individuals living with cystic fibrosis
Read the full story of how patients’ use of Canada’s health systems changes when they start taking Trikafta.
Read snapshot
Methodology notes
Definitions, data sources and methodologies used in the analysis
References
1.
Cystic Fibrosis Canada. . 2023.
How to cite:
Canadian Institute for ºìÁì½í¹Ï±¨ Information. Cystic fibrosis and Trikafta in Canada. Accessed April 5, 2025.
If you would like ºìÁì½í¹Ï±¨information in a different format, visit our Accessibility page.